Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research Award

Posted on by Phenomenological Research

Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research  Award 

Leading Scientist at Nasonova Research Institute of Rheumatology | Russia

Dr. Elena Tchetina is a distinguished researcher in medicine and dentistry, recognized for her impactful contributions to molecular biology and rheumatology. Her academic foundation includes advanced training in microbiology, cell biology, and molecular sciences, supporting a strong interdisciplinary approach to biomedical research. She has extensive experience as a leading scientist and principal investigator, contributing to high-level research in immunology and molecular physiology. Her research interests focus on osteoarthritis, rheumatoid arthritis, and osteoporosis, with emphasis on gene expression, metabolic regulation, and biomarker discovery for disease progression and therapeutic response. Dr. Elena Tchetina has produced 53 documents with an h-index of 18 and has received 8,094 citations across 7,863 documents, reflecting her global research influence. Her work advances translational medicine by connecting molecular insights with clinical applications, strengthening innovative strategies for diagnosis, prognosis, and personalized treatment in rheumatic diseases.

Citation Metrics

8000

7000

6000

5000

4000

Citations
8094

Documents
53

h-index
18

View Scopus ProfileView ORCID Record

Featured Publications

Molecular Mechanisms of Osteoarthritis Progression and Cartilage Degeneration

– International Journal of Molecular Sciences

Gene Expression Signatures in Rheumatoid Arthritis and Therapeutic Targets

– Frontiers in Immunology

Biomarkers for Predicting Disease Progression in Osteoarthritis Patients

– Arthritis Research & Therapy

Metabolic Pathways and Inflammation in Joint Disorders

– Journal of Clinical Medicine

Translational Approaches in Rheumatology: From Molecular Insights to Clinical Practice

– Clinical Rheumatology

Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher Award

Posted on by Phenomenological Research

Dr. Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher Award 

Rehabilitation Department Chair at Local Health Authority Italy

Dr. Cristina Maria Del Prete is a recognized professional in the field of Physical and Rehabilitation Medicine, known for her commitment to advancing innovative healthcare models, interdisciplinary rehabilitation practices, and measurable improvements in patient quality of life. She completed comprehensive medical education and specialized training in rehabilitation medicine, followed by multiple advanced executive and managerial qualifications focused on healthcare systems, organizational leadership, digital transformation, and strategic management. Her education laid a strong foundation for a career that has spanned clinical practice, healthcare administration, academic teaching, and national health policy participation. Over the years, she has held progressive leadership roles within major public healthcare structures, directing rehabilitation departments, coordinating multidisciplinary teams, and overseeing complex service networks involving hospital- and community-based rehabilitation centers. Her responsibilities have included workforce management, budget oversight, strengthening patient-care pathways, improving standards of disability support, and enhancing regional service delivery in alignment with evolving healthcare regulations. She has also actively contributed to national and regional scientific boards, steering committees, and professional societies focused on improving spasticity management, supporting patients with neurological conditions, addressing musculoskeletal pain, and advancing gender-inclusive perspectives within modern healthcare. Her research output reflects a strong blend of clinical relevance and academic rigor, focusing on post-stroke rehabilitation, botulinum toxin interventions in neuromotor disorders, gait analysis, scoliosis management, family coping mechanisms in the context of disability, and the psychological dynamics influencing care outcomes. Her published studies in international peer-reviewed journals demonstrate a dedication to evidence-based rehabilitation, resulting in 63 citations from 55 documents, 7 published scientific works, and an h-index of 4. She has also contributed extensively to academic progress through university teaching appointments across multiple medical programs, where she has trained students in foundational and advanced principles of rehabilitation medicine. International clinical training and professional development programs have further enhanced her expertise and broadened her exposure to advanced rehabilitative technologies, patient-centered methodologies, and global best practices. Throughout her career, she has remained consistently committed to improving health system performance, innovating care delivery frameworks, and conducting research that informs more efficient, equitable, and clinically effective rehabilitation services. Her professional journey reflects a continuous dedication to advancing healthcare quality, supporting both patients and practitioners, and strengthening the scientific foundations of modern rehabilitation.

Profile: Scopus | Google Scholar

Featured Publications:

Del Prete, C. M. (2025). Determinants of sibling relationships in the context of mental disorders. PLoS One.

Del Prete, C. M. (2025). Siblings of persons with disabilities: A systematic integrative review of the empirical literature. Clinical Child and Family Psychology Review.

Del Prete, C. M. (2023). Parentification, distress, and relationships with parents as factors shaping relationships in families with disability. Frontiers in Psychiatry.

Del Prete, C. M. (2022). An observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome. Toxins.

Del Prete, C. M. (2022). Brace treatment in adolescent idiopathic scoliosis: A rehabilitative point of view. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2021). Early botulinum toxin type A injection for post-stroke spasticity: A longitudinal cohort study. Toxins.

Del Prete, C. M. (2022). Efficacy of ultrasound-guided percutaneous lavage and biocompatible electrical neurostimulation in calcific rotator cuff tendinopathy. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2004). Conservative rehabilitative treatment of facial nerve injuries: A critical literature review. Europa Medicophysica.

Del Prete, C. M. (2002). Outcome research in adults with neurological disability. Europa Medicophysica.

Del Prete, C. M. (2001). Therapeutic water exercise in patients with hip arthroplasty. Europa Medicophysica.

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.